Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADRB2 | P07550 | 1/20 | 0.68 |
| ▸ | STAT3 | P40763 | 2/20 | 0.57 |
| ▸ | TOP2A | P11388 | 6/20 | 0.54 |
| ▸ | TOP2B | Q02880 | 6/20 | 0.54 |
| ▸ | KCNH2 | Q12809 | 2/20 | 0.49 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.48 |
| ▸ | HTT | P42858 | 1/20 | 0.47 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.45 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.45 |
| ▸ | HPGD | P15428 | 2/20 | 0.45 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29492858 | 1.00 | ADRB2 (0.68) | ADRB2STAT3TOP2ATOP2BKCNH2 | |
| SCHEMBL143605 | 0.93 | ADRB2 (0.64) | ADRB2STAT3TOP2ATOP2BKCNH2 | |
| SCHEMBL10627001 | 0.93 | ADRB2 (0.66) | ADRB2STAT3TOP2ATOP2BKCNH2 | |
| SCHEMBL9693055 | 0.92 | ADRB2 (0.65) | ADRB2STAT3TOP2ATOP2BKCNH2 | |
| SCHEMBL115991 | 0.92 | ADRB2 (0.62) | ADRB2STAT3TOP2ATOP2BKCNH2 | |
| SCHEMBL7599453 | 0.92 | ADRB2 (0.65) | ADRB2STAT3TOP2ATOP2BKCNH2 | |
| SCHEMBL7575069 | 0.91 | ADRB2 (0.61) | ADRB2STAT3TOP2ATOP2BKCNH2 | |
| SCHEMBL9188190 | 0.91 | ADRB2 (0.61) | ADRB2STAT3TOP2ATOP2BKCNH2 | |
| SCHEMBL5704396 | 0.91 | ADRB2 (0.64) | ADRB2STAT3TOP2ATOP2BKCNH2 | |
| SCHEMBL8735574 | 0.90 | ADRB2 (0.61) | ADRB2STAT3TOP2ATOP2BKCNH2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 96 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-112641773-A | Composition containing heterocyclic compound and use thereof | 黄泳华 | 2021-04-13 | — | — | CN | claimed |
| CN-111150734-A | Compositions containing mixtures of quinolinone derivatives and uses thereof | 黄泳华 | 2020-05-15 | — | — | CN | claimed |
| US-4952695-A | Cyclopropyl-6,7,8-trifluoro-1,4-dihydro-4-oxo-3-quinoline carboxylic acid, intermediate for antibacterials | BAYER AKTIENGESELLSCHAFT (DE) | 1990-08-28 | — | — | US | claimed |
| JP-60222462-A | — | — | None | — | — | JP | disclosed |
| JP-60178867-A | — | — | None | — | — | JP | disclosed |
| CN-111989314-B | Method for hydrolyzing quinolone formate | 拜耳动物保健有限责任公司 | 2024-04-30 | — | — | CN | disclosed |
| EP-3784656-B1 | PROCESS FOR THE HYDROLYSIS OF QUINOLONE CARBOXYLIC ESTERS | ELANCO ANIMAL HEALTH GMBH (DE) | 2023-06-28 | — | — | EP | disclosed |
| US-11332444-B2 | Method for the hydrolysis of quinolonecarboxylic esters | BAYER ANIMAL HEALTH GMBH (DE) | 2022-05-17 | — | — | US | disclosed |
| CN-112641773-A | Composition containing heterocyclic compound and use thereof | 黄泳华 | 2021-04-13 | — | — | CN | disclosed |
| US-20210078950-A1 | METHOD FOR THE HYDROLYSIS OF QUINOLONECARBOXYLIC ESTERS | ELANCO ANIMAL HEALTH GMBH (DE) | 2021-03-18 | — | — | US | disclosed |
| CN-111989314-A | Process for hydrolysis of quinolone formates | 拜耳动物保健有限责任公司 | 2020-11-24 | — | — | CN | disclosed |
| EP-0198678-A2 | A process for preparing substituted quinoline-3-carboxylic acids | WARNER-LAMBERT COMPANY (US) | 1986-10-22 | — | — | EP | disclosed |
| US-4599334-A | 7-(3-aryl-1-piperazinyl)- and 7-(3-cyclohexyl-1-piperazinyl)-3-quinolonecarboxylic acid antibacterials | BAYER AKTIENGESELLSCHAFT (DE) | 1986-07-08 | — | — | US | disclosed |
| EP-0183129-A1 | Quinolonecarboxylic acid derivatives | KYORIN PHARMACEUTICAL CO., LTD. (JP) | 1986-06-04 | — | — | EP | disclosed |
| US-4588726-A | 1-cyclopropyl-6-fluoro-1,4-dihydro-4-oxo-7-(3-oxo-1-piperazinyl)-3-quinolinecarboxylic acid antibacterial agents | BAYER AKTIENGESELLSCHAFT (DE) | 1986-05-13 | — | — | US | disclosed |
| EP-0178388-A1 | Quinolinecarboxylic acid derivatives | KYORIN PHARMACEUTICAL CO., LTD. (JP) | 1986-04-23 | — | — | EP | disclosed |
| US-4578473-A | Process for quinoline-3-carboxylic acid antibacterial agents | WARNER-LAMBERT COMPANY (US) | 1986-03-25 | — | — | US | disclosed |
| US-4556658-A | 7-Amino-1-cyclopropyl-6,8-difluoro-1,4-dihydro-4-oxo-quinoline-3-carboxylic acids and antibacterial agents containing these compounds | BAYER AKTIENGESELLSCHAFT (DE) | 1985-12-03 | — | — | US | disclosed |
| JP-S60222462-A | QUINOLONE CARBOXYLIC ACID AND ITS PRODUCTION | KYORIN PHARMACEUT CO LTD | 1985-11-07 | — | — | JP | disclosed |
| JP-S60178867-A | DIHALOGENOQUINOLINE DERIVATIVE | DAI ICHI SEIYAKU CO LTD | 1985-09-12 | — | — | JP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210078950-A1 | METHOD FOR THE HYDROLYSIS OF QUINOLONECARBOXYLIC ESTERS | NQO2, PGD, ALAD | ADRB2 2182/4885STAT3 4531/4885TOP2A 38/4885 |
| US-11332444-B2 | Method for the hydrolysis of quinolonecarboxylic esters | NQO2, PGD, ALAD | ADRB2 2182/4885STAT3 4531/4885TOP2A 38/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.